Tech and Energy Shine Amid Mixed Pre-Market Landscape

📈 Today's Key Themes

The pre-market landscape presents a mixed picture, with technology and energy sectors emerging as bright spots amidst broader market challenges. Cerillion Plc and Savannah Energy PLC lead the positive sentiment with strong financial results, while companies like XLMedia PLC and Borders & Southern Petroleum plc face significant headwinds. The contrasting performances across sectors highlight the importance of company-specific factors in driving market movements, with some firms demonstrating resilience and growth potential despite ongoing economic uncertainties.

💡 Company Updates

Half-Year Results

Cerillion Plc (#CER) reported resilient half-year results, showcasing adaptability in challenging conditions. Despite a 7% revenue dip to £20.9m, the company demonstrated strength with an 8% increase in recurring revenue to £8.2m and a remarkable 23% surge in its back-order book to £56.5m. The adjusted EBITDA, while down 9% to £10.0m, maintained a robust margin of 47.7%. Management's confidence is evident in a 20% dividend increase, signaling positive future prospects.

Q1 Trading Updates

Savannah Energy PLC (#SAVE) posted impressive Q1 2025 results, with total revenues up 19% to $73.3 million and cash collections increasing by 6% to $124.8 million. The company's net debt reduction from $636.9 million to $597.8 million underscores improved financial health. The completion of the SIPEC Acquisition has led to a 15% production increase at Stubb Creek, positioning Savannah for continued growth. Mobico Group Plc (#MCG) reported a 9% year-on-year revenue growth in Q1, driven by strong performances in its ALSA and North America divisions. ALSA revenues grew by 13% (16% at constant currency), while North America saw a 13% increase. However, challenges persist in the UK and German operations, with revenue reductions of 2% and 3% respectively.

Annual Results

Aurrigo International plc (#AURR) demonstrated significant progress in its annual results, with revenue increasing 34% to £8.9m. The Autonomous division was a standout performer, with revenue surging 433% to £2.9m. Despite an operating loss of £2.5m, this represents an improvement from the previous year's £4.0m loss. The gross margin improved substantially from 22.3% to 41%, indicating enhanced operational efficiency. Dianomi plc (#DNM) faced headwinds in 2024, reporting a 7.3% revenue decrease to £28.0 million. The adjusted EBITDA loss improved slightly to £0.3 million, and the gross margin increased to 26.1% from 24.7%. However, the decrease in active advertisers from 371 to 303 raises concerns about client retention and acquisition challenges.

🎯 Leading Developments

Strategic Changes

In a significant development, XLMedia PLC (#XLM) has proposed the voluntary cancellation of its ordinary shares from trading on AIM. This move is part of an orderly wind-down process following the company's transition to an AIM Rule 15 Cash Shell in November 2024. The cancellation, subject to shareholder approval, is expected to take effect on 18 June 2025. This decision marks a pivotal moment for XLMedia and its shareholders, signaling the end of its journey as a publicly traded company.

Financial Uncertainties

Borders & Southern Petroleum plc (#BOR) faces material uncertainties regarding its ability to meet future commitments, as highlighted in its annual results. The company reported an increased operating loss of $1,159,000 in 2024, up from $1,141,000 in 2023. While the cash balance improved to $2.1 million, the negative operating cash flow of $981,000 and the material uncertainty related to going concern emphasized by auditors underscore the challenges ahead. The company is actively seeking a farm-out partner to fund its Falkland Islands project, which will be crucial for its future operations.

Innovative Partnerships

Arecor Therapeutics plc (#AREC) has established a promising formulation development collaboration with Skye Bioscience. This partnership aims to develop a novel, higher concentration formulation of Skye's obesity candidate nimacimab using Arecor's proprietary Arestat™ technology. Skye Bioscience will fund Arecor's development activities, with the option to license rights to the new proprietary formulation. This collaboration aligns with Arecor's strategy of bringing innovative medicines to market that address significant unmet patient needs, potentially opening new revenue streams for the company.

📅 Week Ahead

20 May 2025: Smiths Group plc (#SMIN) Q3 Trading Update
20 May 2025: Diploma PLC (#DPLM) Half Year Results Release
20 May 2025: LondonMetric Property Plc (#LMP) Announcement of full year results
20 May 2025: Cranswick plc (#CWK) Preliminary results announcement
21 May 2025: SSE plc (#SSE) Full-year results presentation and Q&A session
21 May 2025: Intermediate Capital Group plc (#ICG) Full year results announcement
21 May 2025: JD Sports Fashion Plc (#JD.) FY25 results/Q126 update
21 May 2025: HICL Infrastructure PLC (#HICL) Annual Results Announcement
22 May 2025: Investec Group (#INVP) Full year results release
22 May 2025: Johnson Matthey Plc (#JMAT) Announcement of results for the year ending 31st March 2025

View full calendar

Market Summary